CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0449

Exemestane (Aromasin) Raw

Filed under Raw Materials. The bureau holds 107 laboratory returns for this compound from 32 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

32 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 7 10.0 9.9 10.0 14 Nov 2025 16 Apr 2026
Sigma-AldrichCASE #VI-2026-0829 A 4 10.0 9.9 10.0 28 Jun 2026 7 Aug 2026
JEEP PeptidesCASE #VI-2026-0457 A 3 10.0 9.9 10.0 21 Jan 2026 3 Jul 2026
BachemCASE #VI-2026-0314 A 3 10.0 9.9 10.0 10 Feb 2026 8 Jul 2026
Kerui PeptidesCASE #VI-2026-0626 A 3 10.0 10.0 10.0 15 Apr 2026 2 Jul 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 3 10.0 10.0 10.0 19 Apr 2026 22 Jun 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 3 10.0 9.9 10.0 10 Feb 2026 19 Jun 2026
WuXi TIDESCASE #VI-2026-0335 A 3 10.0 9.9 10.0 11 Apr 2026 17 Jul 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 3 10.0 10.0 10.0 11 Mar 2026 18 Jul 2026
GenScript PeptidesCASE #VI-2026-0860 A 3 10.0 10.0 10.0 16 May 2026 18 Aug 2026
AmbioPharmCASE #VI-2026-0177 A 3 10.0 9.9 10.0 3 Mar 2026 8 Jul 2026
Sangon BioCASE #VI-2026-0671 A 2 10.0 10.0 10.0 24 Jun 2026 5 Jul 2026
HomopeptideCASE #VI-2026-0760 A 4 9.9 9.9 10.0 24 May 2026 24 May 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 4 9.9 9.9 10.0 11 Mar 2026 1 Jul 2026
QYAOBIOCASE #VI-2026-0861 A 4 9.9 9.9 9.9 24 Apr 2026 27 May 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 4 9.9 9.9 10.0 6 Nov 2025 27 Jun 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 4 9.9 9.9 10.0 14 Mar 2026 16 May 2026
SinoPepCASE #VI-2026-0387 A 4 9.9 9.9 10.0 21 Apr 2026 1 Aug 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 3 9.9 9.9 10.0 24 May 2026 9 Jun 2026
Hubei JianxiangCASE #VI-2026-0048 A 2 9.9 9.9 10.0 21 May 2026 11 Jun 2026
PolyPeptide GroupCASE #VI-2026-0143 A 2 9.9 9.9 10.0 26 Dec 2025 19 Feb 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 2 9.9 9.9 10.0 5 Apr 2026 2 Jun 2026
AsymchemCASE #VI-2026-0091 A 2 9.9 9.9 9.9 17 May 2026 20 May 2026
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 8 8.7 7.7 10.0 24 May 2026 24 May 2026
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 6 8.6 6.6 9.9 24 May 2026 24 May 2026
Glbiochem (Shanghai)CASE #VI-2026-0704 A 4 8.4 7.4 9.5 24 May 2026 24 May 2026
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 6 8.3 6.7 10.0 24 May 2026 24 May 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 3 7.9 6.9 8.6 21 May 2026 21 May 2026
Richards Biotech Simply RichardsCASE #VI-2026-0307 X 1 5.0 5.0 5.0 27 Feb 2025 27 Feb 2025
Zenith Jove Peptide ZJCASE #VI-2026-0570 X 1 3.9 3.9 3.9 13 Feb 2025 13 Feb 2025
Platinum CryoCASE #VI-2026-0406 X 2 3.7 3.1 4.2 17 Dec 2024 17 May 2026
SubQ SocietyCASE #VI-2026-0716 X 1 0.0 0.0 0.0 3 Jul 2025 3 Jul 2025

Open any subject to view the batch-level evidence for Exemestane (Aromasin) Raw alone.